Parrot David 4

What Happened

• David Parrot, Chief Financial Officer of Scribe Therapeutics (SCTX), made two open-market purchases on July 23, 2026: 1,333 shares and 1,333 shares at $15.00 each, totaling 2,666 shares for $39,990.
• The filing also reports derivative awards (grants) totaling 227,761 shares: a March 13, 2026 grant of 8,909 derivative shares and two July 23, 2026 grants of 109,426 derivative shares each. The awards are reported with a $0 price (derivative awards/stock-based compensation).

Key Details

• Transaction dates and prices:
  • 2026-07-23: Open-market purchases — 1,333 shares @ $15.00 and 1,333 shares @ $15.00 (total $39,990).
  • 2026-03-13: Grant of 8,909 derivative shares reported at $0.
  • 2026-07-23: Two grants of 109,426 derivative shares each reported at $0.
• Total derivative shares granted (per filing): 227,761.
• Shares owned after transaction: Not specified in the details you provided; check the full Form 4 for post-transaction beneficial ownership.
• Notable footnotes from the filing:
  • F1: One transaction occurred prior to the issuer’s registration under the Exchange Act and is reported under Rule 16a-2(a).
  • F2: At least one option award is fully vested.
  • F3: Some options vest 1/48 monthly over four years, with the first tranche scheduled Aug 23, 2026, subject to continued service.
  • F4: Some options vest only upon achievement of market-based performance criteria during July 23, 2026–July 23, 2029, subject to continued service.
• Filing date vs. transaction dates: The Form 4 was filed on 2026-07-27 while some transactions occurred on 2026-03-13 and 2026-07-23; footnote F1 indicates earlier pre-registration activity was reported under Rule 16a-2(a). Review the filing for any timeliness notes.

Context

• The open-market purchases (2,666 shares for ~$40k) are straightforward cash purchases by the CFO and are generally more informative to investors than routine sales—though they do not by themselves indicate company outlook.
• The awards are reported as derivative grants at $0; these are likely stock-based compensation (options or RSUs) and include a mix of fully vested, time-based vesting, and market-performance-based vesting. Vesting conditions (service and performance) will determine when/if these shares become exercisable or deliverable.
• For retail investors: focus on the cash purchases as a small insider buy and monitor future SEC filings for when/if the derivative awards vest or are exercised/sold.